Everything Genetic’s Post

Understand Your Patient's Risk of Developing Breast and Ovarian Cancer as a Second Primary with the Everything Genetic 12 Gene Breast Cancer Panel. The test looks at all the important genes associated with inherited breast and ovarian cancer, particularly BRCA1, BRCA2, and 10 other important genes. A woman with a pathogenic variant in the gene BRCA1, for example, has a 50-80% risk of developing breast cancer, while the average woman has a risk of only 10%. Understanding that risk will allow for tailored screening, early detection, and better prevention of cancer. Find out more: https://buff.ly/3xbhT8d Our Medical Director, Dr James Mackay talks about who this panel is suitable for in the short video below ⬇️ #BreastCancer #BreastCancerTest #GeneticTestForBreastCancer #12GenePanel #UKGeneticTest #GeneticTesting #NGSTesting #GeneticTest #BreastCancerRiskTest #BreastCancerRisk #CancerPrevention #CancerTreatment #CancerDiagnosis

Faster Results for Clinicians Treating Breast Cancer Patients Waiting for test results can be a big setback in clinical cancer care, especially if preventative treatment may be urgently required. The Everything Genetic 12 Gene Breast Cancer Panel is delivered from a UK laboratory, allowing you to receive clinically actionable results in just 2–3 weeks. This allows you to quickly determine best next steps for treatments and implement the right preventative care for your patients. By identifying the disease-causing variant, the 12 Gene Breast Cancer Panel can also guide testing and management of at-risk relatives. Find out more: https://buff.ly/3xbhT8d Listen what our Medical Director, Dr James Mackay, has to say about this test in the video below ⬇️ #BreastCancer #BreastCancerTest #GeneticTestForBreastCancer #12GenePanel #UKGeneticTest #GeneticTesting #NGSTesting #GeneticTest #BreastCancerRiskTest #BreastCancerRisk #CancerPrevention #CancerTreatment #CancerDiagnosis

About 1 in 3 people in the United States will develop cancer during their lifetime, highlighting the prevalence of this disease. In some cases, cancers within a family are linked to an inherited gene mutation, emphasizing the importance of hereditary cancer screening. October is breast cancer awareness month, a time to raise awareness and educate others. Today, I had the opportunity to advocate for hereditary genetic cancer screening alongside my teammates and colleagues. Let's spread the word and promote early detection! #breastcancerawareness💝 #Questdiagnostics Learn more about hereditary cancer screening: https://lnkd.in/gsAQTyGb

October is Breast Cancer Awareness Month! 🌸 This month, we're highlighting the importance of BRCA gene testing in assessing breast cancer risk. Mutations in the BRCA1 and BRCA2 genes can significantly increase the likelihood of developing breast and ovarian cancers. Key Insights: - BRCA1 mutations: Up to 72% increased risk for breast cancer. - BRCA2 mutations: Up to 69% increased risk, often more treatable. Genetic testing is a proactive step for those with a family history of cancer. Knowing your BRCA status can lead to earlier screenings and informed health decisions. For more details, check out our recent blog post: https://lnkd.in/dt-mDUpw

This is it. If you’ve ever lost sleep over breast cancer. This is it. If you’re someone with a family history of breast cancer. If you’re someone with a genetic predisposition to breast cancer. If you’re someone with dense breasts. This is it. If you’re someone who believes in unlocking the quality-of-life preservation that exists at the earliest stages of breast cancer. This is it. If you’ve been following our journey. If you’ve been wondering how to get involved. This is it. Mammogen is ushering in the next century’s worth of impact in breast health. Help us help you. Click the link. Get involved. Be the change. This is it.

Hereditary Cancer Awareness Week! 🧬 About 10% of cancers may be linked to inherited genes. Having a cancer-related gene doesn't mean that you will get #cancer, but it does raise your risk. #BRCA1/ #BRCA2 testing is useful for detecting breast and ovarian cancer risk, but multigene testing goes further. It looks at multiple genes, including BRCA1/BRCA2, to identify a wider range of hereditary cancers like colorectal and endometrial cancer. By choosing multigene testing, you and your family can get a more complete picture of your cancer risks, helping physicians create a better, personalized plan for prevention. Knowing your genetic cancer risk is important in protecting your future health. Find out who should undergo the HerediGENE® genetic test for hereditary cancer: 🔗https://lnkd.in/dQfzmANC

📢 🚨 We need YOU! 🚨 Mammogen is gearing up to launch our groundbreaking clinical trial, but we can't do it alone. We're looking for individuals who may: 🎗 Have a family history of breast cancer 🎗 Carry an inherited gene mutation associated with breast cancer 🎗 Have dense breasts 🎗 Be interested in finding out more about eligibility **Please note you DO NOT have to meet all the indications listed! You might meet one of them, or all of them. Either way, we would love to have you sign up to learn more!** Your participation can help shape the future of breast cancer detection, and together, we can make early detection more accessible and accurate than ever before. Interested? Click the link below to learn more and find out if you’re eligible to join us on this journey! Let’s make history—one step at a time. 🌸 🔗 https://lnkd.in/eu-irq3P #BreastCancerAwareness #ClinicalTrial #EarlyDetection #BreastHealth #Mammogen #DenseBreasts #GeneticScreening #BreastCancerResearch #InnovativeHealthcare #LiquidBiopsy

🔬 BRCA1/2 gene mutations play a pivotal role in breast cancer diagnosis and treatment planning, making accurate detection more crucial than ever. LGC Clinical Diagnostics provide advanced tools and solutions to support laboratories in ensuring precise and reliable BRCA1/2 testing. This blog delves into the importance of comprehensive BRCA1/2 diagnostics, the use of certified reference materials, and how these innovations are empowering personalised breast cancer treatments. Explore how we’re helping labs deliver confidence in their results and advancing the future of breast cancer care: https://ow.ly/1F2b50TA2Uy #ScienceforaSaferWorld #BreastCancerAwarenessMonth #BRCA #ClinicalDiagnostics #PersonalisedMedicine #Genomics #PrecisionDiagnostics https://ow.ly/1F2b50TA2Uy

➡️ The clinical utility of genetic testing in hereditary pancreatic cancer During Genekor's participation in the conference "From Oncogenesis to Therapy," Varvara Kevisa Potska, MSc, member of Genekor's hereditary Cancer team, presented the study conducted in our laboratory on the multi-gene screening of 184 patients with pancreatic cancer using next-generation sequencing (#NGS) technology. 📍 The results of the study showed that a pathogenic/likely pathogenic variant was identified in 21% of pancreatic cancer patients. These findings may benefit physicians in the clinical management of their patients and the selection of an appropriate therapeutic approach, as well as the individuals themselves and their family members regarding their family planning and the investigation of the transmission of pathogenic genes to immediate relatives. #Genekor #pancreaticcancer #hereditarycancer

A recent study by Le Compte et al. illustrates how RNA-Seq can be used to characterize organoids as models for cancer treatment and identify intra-patient response heterogeneity in pancreatic ductal adenocarcinoma, one of the most lethal cancers. RNA-Seq provides a powerful tool that can be used to study gene expression in organoids, and allows identification of genes that are associated with #cancer progression and #drug resistance to develop new therapies for pancreatic cancer in the future. Read the full article: https://lnkd.in/dKCtY5XT 🚀 Ready to start your #RNAseq experiments for #organoids? ⭐ Lexogen is your trusted #NGS partner for drug discovery workflows and cancer models. 💰 Save up to 50% with limited service offer until the end of 2024! Go here for all details: https://lnkd.in/gtrYYC8D #DrugDiscovery #GeneExpression